Current Headlines

  1. FDA Approves Genentech’s Xolair (omalizumab) For Allergic Asthma In Children

    Genentech, a member of the Roche Group , recently announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) to treat moderate to severe persistent asthma in children six to 11 years of age, who have had a positive skin test or in vitro reactivity to an airborne allergen and have symptoms that are inadequately controlled with inhaled corticosteroids4

  2. Teva Announces FDA Acceptance Of New Drug Applications For Fluticasone Propionate/Salmeterol And Fluticasone Propionate RespiClick Inhalers

    Teva Pharmaceutical Industries Ltd. announced recently that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug applications (NDAs) for two products for adolescent and adult patients with asthma

  3. Sartorius Acquires Cell Screening Specialist IntelliCyt

    Sartorius, a leading international pharmaceutical and laboratory equipment provider, recently announced the acquisition of U.S. based IntelliCyt Corporation, an award-winning innovator and manufacturer of novel cell screening platforms used in drug discovery.

  4. Certara Introduces The D360 Express Data Platform For Biotech R&D

    Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, recently announced the availability of D360 Express

  5. FDA Grants Breakthrough Therapy Designation For Incyte’s Ruxolitinib (Jakafi) In Acute Graft-Versus-Host Disease (GVHD)

    Incyte Corporation recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host disease (GVHD)

  6. Cobra Biologics And Alligator Bioscience Extend Drug Development Partnership

    Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, has been contracted to develop a second cell line for Alligator Bioscience AB (Alligator), a Swedish biotechnology company.

  7. Yumanity Therapeutics And The New York Stem Cell Foundation Research Institute Announce Discovery Collaboration

    Yumanity Therapeutics, a company focused on transforming drug discovery for diseases caused by protein misfolding, recently announced a discovery collaboration with the New York Stem Cell Foundation (NYSCF) Research Institute, a non-profit organization dedicated to accelerating cures for major diseases through stem cell research

  8. WAVE Life Sciences Receives Orphan Drug Designation From FDA For Its Lead Candidate Designed To Treat Huntington’s Disease

    WAVE Life Sciences Ltd., a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, recently announced that its lead candidate WVE-120101, which is being investigated for the treatment of Huntington’s disease (HD), has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA)

  9. University Of Southampton Leverages Medidata Clinical Cloud To Bridge Innovation Gap Between Academia And UK Drug Development Industry

    Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, and the Southampton Clinical Trials Unit at the University of Southampton recently announced a partnership to accelerate drug development across the United Kingdom

  10. Unum Therapeutics Announces Active Investigational New Drug (IND) Application For ACTR087 In Patients With Relapsed/Refractory B-cell Lymphoma

    Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, recently announced that the investigational new drug (IND) application for ACTR087 for the treatment of adult patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, is now active